PLD 103
Alternative Names: PLD-103Latest Information Update: 20 Oct 2022
At a glance
- Originator PeLeMed
- Class Antineoplastics
- Mechanism of Action TEA domain transcription factor inhibitors; YAP-signaling protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 14 Oct 2022 Early research in Cancer in South Korea prior to October 2022 (unspecified route) (PeLeMed pipeline, October 2022)